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Summary.-The results from an international survey of 15 major cancer centres have
clarified how randomization is being implemented in cancer trials. As regards the
mechanics of obtaining treatment assignment for each patient a system of telephone
registration to a central randomization office was widely used. We also advise
formal checks for patient eligibility immediately before treatment assignment, and
subsequent written confirmation of randomization to the investigators. As regards
statistical methods, stratification of randomization by one or two prognostic factors
(and institution in multicentre trials) is commonplace. Most centres used the stand-
ard approach of random permuted blocks within strata though some others used
"dynamic" institution-balancing or "minimization" methods instead. The value of
stratified allocation is chiefly for the trial's credibility in having comparable treat-
ment groups, rather than for statistical efficiency. One should avoid overstratifica-
tion and use only the really important prognostic factors. One essential is that
randomization should in practice work for every patient, so undue complexity is to
be avoided.
THIS ARTICLE has two main objectives:
to describe current approaches to imple-
menting randomization by presenting the
results of a survey of 15 major cancer trial
centres in Europe and the United States,
and to make recommendations regarding
how randomization should be carried out.
We shall not deal with the controversy
over whether studies should be random-
ized, and so shall not consider any
alternatives to randomization. That is, we
wish to tackle the question how to
randomize, rather than why.
In considering randomization methods
it is convenient to consider 2 main topics:
Mechanics.-How should treatment
assignment actually be obtained for each
patient entering a trial? Such issues as
assignment by phone or by sealed envel-
opes, the sequence of events for patient
registration, and requisite documentation
are considered here.
Statistical methods.-What methods
should be used to set up the randomization
procedure for a trial? For example, are
methods other than randomized permuted
blocks worth considering, and is stratifica-
tion necessary?
We recognize that there is no single
approach that is suitable for all centres or
for all trials. Hence, our recommendations
represent a balance between theoretical
efficiency and practical feasibility.
A SURVEY OF CANCER-TRIAL CENTRES
There are several articles describing how
randomization and patient registration could
be carried out in clinical trials (e.g. Herson,
1980; Pocock, 1979; Zelen, 1974). There also
exist many more statistical papers which
discuss the theoretical properties of various,
sometimes very complex, randomization
schemes. Our survey was designed to discover
the methods by which randomization is
actually being performed in cancer centres,
why they are used and how well they seem
to be working.RANDOMIZATION IN CANCER TRIALS
We could have directed our enquiries at a
random sample of trials or of cancer centres,
but this seemed impracticable and not par-
ticularly useful. Instead, it seemed more
informative to undertake a detailed enquiry
at a limited number of established centres
which were experienced at coordinating
clinical trials. The 15 centres included in our
survey are listed below:
Organization
Institut Gustave Roussy
Cancer Research Centre of the U.S.S.R.
Academy of Medical Sciences
European Organization for Research
on Treatment of Cancer
Medical Research Council Cancer
Trials Office
Christie Hospital
Oxford Clinical Trials Centre
Scottish Breast Group
Memorial Sloan-Kettering Cancer Center
Northern California Oncology Group
Biometry Branch of National
Cancer Institute
Mayo Clinic
University of Texas System Cancer
Center
Cancer and Leukemia Group B
Childrens' Cancer Study Group
Eastern Cooperative Oncology Group
The method ofenquiry was for one or both
of us to visit each centre, or otherwise meet
the persons responsible for randomization
procedure. In an interview with a formal
questionnaire to guide us through, we would
enquire about the randomization procedures
used. We also obtained, as an example,
specific details of one particular trial, usually
the most recent primary breast cancer trial,
for each centre.
The centres chosen offer a wide geographic
coverage in Europe and North America and
represent a broad cross-section of cancer
trials. Both large multicentre cooperative
groups and smaller in-house trials at specific
hospitals are included, as well as centres
focussing on certain tumour types.
The centres varied considerably in the scale
of operation: 8 had >30 currently active
trials, while another 3 had < 10. All centres
were involved in multicentre trials, though
in 3 most of the trials were confined to their
own hospital.
Mechanics of Treatment Assignment
The great majority of centres (12/15) used
a system of centralized registration by tele-
phone as the main method of obtaining treat-
ment assignment. The 3 other centres used a
system of sealed envelopes; in one this was
preferred because of language problems in
multicentre trials across several countries. A
few ofthe other centres used sealed envelopes
on a limited basis, for their more remote
(e.g. overseas) institutions. One centre re-
ported "cheating" by an institution which
had opened all envelopes in advance.
Location
Paris
Moscow
Brussels
Contact
R. Flamant
A. Klimenkov Continental
R. Sylvester Europe
Cambridge L. Freedman
Manchester M. Palmer .U.K.
Oxford R. Peto |
Edinburgh R. Prescott J
New York D. Braun )
San Francisco B. Brown
Bethesda D. Byar |
Rochester T. Fleming
Houston E. Gehan
New York 0. Glidewell
Los Angeles H. Sather
Boston K. Stanley
Three centres had undertaken double-
blind studies with telephone randomization:
2 had "blinded" drug packages sent in
advance to each centre and the appropriate
number was given over the phone, whilst the
third arranged for the hospital pharmacists
to phone for randomization.
Informed patient consent before randomiza-
tion is a legal requirement for all the U.S.
trials. One centre reported that the telephone
randomization and patient consent were
sometimes carried out simultaneously. How-
ever, there was no such requirement in the
7 Europeancentres. Twosuchcentresreported
that it was up to each local institution to
decide on the degree of informed consent
that was needed.
In 8 centres a check on patient eligibility
was undertaken as part of the telephone
randomization. This varied from a rather
informal general enquiry in some centres to
a formal itemized list of checks in others. In
one centre, eligibility checks for in-house
studies were done in person by the data
manager and investigator. With sealed
envelopes there is no real scope for eligibility
checks.
As regards pretreatment documentation it
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was standard practice to keep a randomiza-
tion log sheet for each study. For trials with
sealed envelopes this relied on investigators
notifying the centre. Of the 12 centres using
telephone randomization only 4 sent written
confirmation of treatment assignment to the
institution entering the patient. Centres
varied as to what information was asked for
over the phone: all required the patient's
name, stratifying factors (including the
centre which did not use stratified randomiza-
tion) and institution. Some also required the
physician's name, name of person phoning
and patient's date of birth.
WTe asked each centre about any practical
problems occurring during randomization
and registration of patients. It is difficult to
quantify this information, but brief comment
seems worthwhile. All centres reported that
some ineligible patients were randomized into
studies, though those centres with formal
eligibility checks at randomization reckoned
the problem was minor, say <5o. One
centre had documented that 6% of random-
ized patients were later classified as ineligible,
this forming part of an annual statistical
assessment of what problems arose in each
collaborating institution. Another centre
reported a rate of 700 known ineligible
patients, plus 3% who were considered
ineligible because no on-study form was
received. Two centres declared that ineligible
patients were included in the analysis of
results, whilst some others tended to exclude
them.
Most centres reported there were no non-
randomized patients entering their random-
ized studies. Two centres reported that a
few such patients had entered studies which
used sealed-envelope randomization, and
another recalled a past problem with non-
randomized cases. Two centres permitted
some non-randomized patients to follow the
No. ofstratifying factoirs
(other than institution)
0
0, except for one trial
0-1
0-2
1
1, or occasionally 2
1-2
Typically 3
2-3
2-4
2-5
Typically 2
.3
protocol of randomized studies, though such
cases were reported separately.
Centres generally reported only a small
proportion of early patient withdrawals,
though one centre quoted 400 of such cancel-
lations. In general, this problem was mostly
related to patient refusal. Most centres
included such patients in subsequent trial
reports, though two appeared to exclude
such refusals from further analysis, which
might in principle engender slight bias.
One centre made use of a computer during
registration and randomization of each
patient. The person at the operations office
keyed in eligibility and stratification informa-
tion, while the institution was on the phone,
and a computer algorithm based on the
'"minimization" method described below
determined the treatment assignment, which
was then conveyed to the phoning institution.
Statistical Methods for Randomization
For the 15 centres in our survey the most
common approach was to produce randomiza-
tion lists before the trial started, using the
method of random permuted blocks within
strata. This means that patients were cate-
gorized into several different strata based on
specific patient prognostic factors. A separate
list of random treatment assignments was
then produced for each patient type, making
sure that each such list had equal numbers
on each treatment every so many patients.
This general approach was standard practice
in 13/15 centres, though there was consider-
able variation over details.
First, consider the issue of stratification.
How many patient factors (other than their
institution) were used to form strata? This is
hard to quantify, since trials involve different
numbers of patients and treatment groups.
However, it is informative to list the separate
reports from each centre as follows:
No. of strata
1
1
1-2
1-4 European centres
2-4
2-4
2-4
24
Typically 8 U.S. centres
4-50
4-6
<8 J
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Clearly, there is great diversity in the
amount of stratification used. The American
centres were generally more in favour of
stratification than the European centres.
Indeed 2 European centres generally did not
stratify by any factor other than institution,
and 2 more had some trials without stratifica-
tion. No centre had used more than 5 patient
factors for random permuted blocks within
strata.
Some form of institution balancing, to
ensure that similar treatment numbers occur
within each institution, was standard prac-
tice for all except one of the centres with
multicentre trials. This was usually done by
having institution as another stratifying
factor, the only such factor in 2 centres. Two
other centres adopted a dynamic system: if
the treatment difference within the next
patient's institution exceeded a certain
number (say 2 or 3) the conventional stratified
random assignment was interrupted and the
treatment with the smallest number in that
institution was assigned to that patient.
Two other centres included institution as
another factor in the minimization method
described below.
The most common choice of size of random
permuted blocks within each stratum was
twice the number of treatments. One centre
was more restrictive, using blocks of 2 for
2-treatment trials. No centre used blocks of
more than 10 patients. One centre used blocks
of 2-4 patients in small trials and 6-8
patients in larger trials. Another centre used
block sizes from 1-4 times the number of
treatments, varied at random within each
trial.
Seven centres used a computer program
to generate the randomization lists before
initiating a trial, whilst others used tables of
random numbers.
Four centres had used another rather
different method, sometimes called "mini-
mization", for achieving stratified randomiza-
tion. One of these centres always used this
method, another in 80% of trials and the
other 2 in one specific trial. This method may
be best illustrated by an example from one
centre, a head-and-neck trial with 3 relevant
factors: 15 institutions, 7 disease sites and
nodal involvement (+ or -). For conven-
tional stratification this leaves 15 x 7 x 2 =210
strata, which is clearly impractical for ran-
dom permuted blocks. The minimization
method attempts to balance dynamically the
treatment groups each time a patient is
entered into the study. One checks for each
possible treatment assignment, what would
be the resultant difference in treatment
numbers within his institution, his disease
site and his nodal involvement category.
One then uses these differences to define an
imbalance score for that treatment (e.g. the
sums of squared differences is often used, and
is equivalent to the simple calculation given
below). One assigns the treatment with the
smallest imbalance score.
For instance, suppose 260 patients had
entered the above-mentioned head-and-neck
cancer trial, and that the next patient was
from the Royal Marsden Hospital, Sutton,
had cancer of the oropharynx and no nodal
involvement. The numbers of patients on
each treatment in each of these 3 categories
were as follows:
Misonidazole
No nodal involvement 80
Cancer of oropharynx 25
Royal Marsden Hospital 13
Sum= 118
Placebo
80
23
14
117
This column total is smaller on placebo,
in which case placebo is assigned to that next
patient. If the sums were equal, treatment is
assigned at random. Therearevarious possible
elaborations on minimization, which become
feasible if a computer is available at the time
of randomization; the above example has
the advantage of simplicity. Implementation
requires a current record of numbers of
patients on each treatment for each level of
each factor, i.e. (15+7+2) x 2=48 numbers,
of which 6 are used at any one assignment.
In practice, the necessary calculation can be
done while the investigator is on the phone
waiting for the randomized assignment.
In using minimization there is no particu-
lar restrictive limit on the number of strati-
fying factors; e.g. a trial for lung cancer at
another centre stratified by age, extent of
disease, histology, sex, performance status
and institution. White & Freedman (1978)
and Miller et al. (1980) give further details of
minimization and other statistical methods.
The use ofunequal randomization, i.e. more
patients on one treatment than another, was
not very common, though 7 centres had tried
it. The future of unequal randomization will
depend on the experiences in recent trials
where it has been used.
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We have so far discussed stratification in
general terms. One key specific issue is
deciding which patient factors to stratify by.
To illustrate this problem we focus on trials
for primary breast cancer. Ten centres had
an active primary breast trial and the
factors (other than institution) which they
used for stratification are listed below
(centre numbers do not correspond to the
earlier list of centres).
Centre Stratification factors
None
2 None
3 rStages I or II
Pre- or post-menopausal
4 I+ve nodes (+ or -)
tRadiotherapy (+ or-)
5 fNo. +ve nodes
lPre- or post-menopausal
6 fSimple or radical mastectomy
Pre- or post-menopausal
rNo. +ve nodes, (1-3 or 4+)
7 Pre- or post-menopausal
OGestrogen receptor, (+ or-)
rNo. +ve nodes, (0-3 or 4+)
8 ) Tumour size, (<3 or >3 cm)
Pre- or post-menopausal
LUnfavourable signs (+ or-)
9 No. +ve nodes, (1-3 or 4+)
Oestrogen receptor, (+ or -)
rNo. +ve nodes (1-3 or 4+)
Pre- or post-menopausal
10 Tumour size (< 2, 2-5 or > 5 cm)
Radiotherapy (+ or -)
LOestrogen receptor, (+ or-)
Evidently a variety of choices has been
made. Two trials had no factors (+ or -)
while another had 5 factors, with a total of
48 strata. One can see some consistency in
the choice of factors, no. +ve nodes and
menopausal status being fairly standard.
Some of the trials were without these patient
factors, because they were restricted to node
-ve or pre-menopausal patients. Perhaps
the reliability and value of oestrogen receptor
status for stratifying might be questioned.
The inclusion of tumour size as a stratifying
factor appears to depend on the number of
strata a centre considers appropriate and
manageable.
RECOMMENDATIONS
Having reviewed how various cancer
centres handle patient registration and
randomization, we will make some general
recommendations:
Telephone randomization.-For multi-
centre trials, the most reliable means of
randomizing patients is to have the
investigator telephone a coordinating
centre each time he enters a patient. The
alternative of using sealed envelopes at
each institution does not allow central
monitoring of randomization procedure,
and carries a greater risk of things going
wrong. If cental randomization is not
feasible (e.g. in some international trials)
sealed envelopes may have to be used. It is
then important to monitor patient entry
retrospectively to check that the scheme
was followed. For single-centre trials, one
should aim for the same formal approach
via a randomization office. If, however,
personal contact then replaces the tele-
phone call, formal procedures may be
necessary to prevent the next treatment
being known before the final decision is
made to admit a particular patient.
Eligibility checks.-Some centres under-
took a formal check that each patient was
eligible for the trial immediately before
treatment was assigned. We endorse this
approach as an effective method of
reducing the number of patients mis-
takenly put on to a trial. While one can try
to preserve a trial's validity by retro-
spectively eliminating ineligible cases,
suspicions may arise ifit occurs frequently.
More importantly, the inclusion of inelig-
ible patients in a study may mean that
they fail to receive the best treatment for
their disease. Whether to include or
exclude ineligible patients in the analysis
of trial results should ideally be stated in
the study protocol, so as to avoid any
biased decisions later.
Confirmation of randomization.-In
multicentre trials, it is advisable to follow
up telephone randomization, by sending
the investigator a written confirmation of
patient entry and treatment assignment.
This was only done in a few centres, and
one wonders what drops-outs might occur
in other centres due to lack of confirma-
tion. One can also include with the
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confirmation notice an opportune re-
minder of certain aspects of protocol such
as when patient data are to be submitted.
Representative patient entry. One prob-
lem in many trials is that they only include
a small, relatively select proportion of
eligible patients, and this may make the
results unrepresentative. Hence it is desir-
able to ensure that as many eligible
patients as possible actually enter a trial.
Investigators who fail to do this are
generally showing a lack ofcommitment to
the trial, and are liable to weaken the
quality of research. Hence, it may be
advisable to exclude such half-hearted
participants.
Informedpatient consent. Each country
has its own regulations on this issue. In
particular, there are legal requirements in
North America, but a more informal
approach in most European countries. In
some of the latter it remains common
practice not to inform patients they have
cancer, so that the general desirability of
seeking informed consent must be
reconsidered.
The sequence of events.-The essential
aspect of randomization is that the
investigator cannot anticipate in advance
which treatment any given patient will
receive. One approach is to ensure, before
treatment assignment is given, that both
investigator and patient are willing to
accept randomization, and that the
patient has formally entered the trial. One
may then reduce the number of early
patient drop-outs due to investigator or
patient refusal of treatment. An alterna-
tive is to seek patient consent after the
treatment allocation is known (bias being
avoided by analysing the data by allocated
rather than actual treatment). Zelen
(1979) discusses such "randomized consent
designs".
Statistical methods for randomization.
The simplest method is to prepare a single
randomization list in advance, using a
table of random numbers. This is the
equivalent of tossing a coin and has the
advantages of simplicty, unpredictability
and hence reliability. Its disadvantage is
that one has no guarantee that the
treatment groups will be similar in size and
in type of patient, though in large trials
marked imbalances are unlikely to occur.
However, it is common practice to impose
some form ofrestriction on randomization
to ensure reasonable balance, and the
remainder of this paper discusses the
various options.
Random permuted blocks.-One can
arrange each randomization list so that it
has equal treatment numbers every so
many patients, by using random permuted
blocks. The number of patients per block
will depend on the extent of stratification
(see below) but should preferably not be so
small as to enable investigators to predict
the next assignment, nor so large as to
allow serious inequality mid-block.
Institution balance.-In multicentre
trials it is desirable to have roughly equal
patient numbers on each treatment within
each institution. In the statistical methods
section we described 3 possible approa-
ches; the choice will depend on the extent
of other stratification.
Stratification. In principle it seems
useful to take account of patient factors
affecting response, by trying to arrange
comparable treatment groups. The stand-
ard approach is to choose a few such
factors, accordingly divide patients into
different strata, and use the method of
random permuted blocks within each
stratum. The problem is to know which
and how many patient factors it is feasible
to stratify by.
lVhich patient factors?-One should
stratify only by factors that are known, or
thought very likely, to affect response.
Clinicians often favour rather "technical"
factors such as oestrogen receptors or
histological classification, whereas it often
turns out that more "patient-orientated"
factors such as weight loss or performance
status have a greater bearing on patient
response. For instance, in all studies of
advanced disease one should stratify by
performance status. One should generally
avoid arbitrary stratification by factors
which though of clinical interest, may
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have little relevance to prognosis. Such
factors can be dealt with satisfactorily in
the analysis of results, but need not affect
trial design. Also, one should stratify only
by factors that are reliably reported at the
time of randomization. For instance,
tumour pathology may be unsuitable if
local hospital pathologists are inconsistent
or if one has to wait for a centralized
diagnosis.
How manyfactors?-Ifinstitution is one
of the stratifying factors in a permuted
block design, one can usually include at
most 1-2 other factors into the determina-
tion of strata. Otherwise the number of
strata becomes too large and this may
actually reduce the chances of balance
with respect to any individual factor. If
institution balance is done by the dynamic
system (see Statistical methods) it may be
possible to have allocation stratified for
3-4 patient factors.
Minimization.-As explained earlier,
one or two centres have opted to use
minimization methods for treatment allo-
cation. The advantage is that more patient
factors can be included, but it requires a
certain amount of calculation as each
patient is randomized. The method seems
workable in those centres that have tried
it, though some others might find it more
awkward. Further experience may more
clearly identify the role of minimization.
The method should be particularly valu-
able in trials of limited size, in which
several factors are known toaffect reponse.
Is imbalance a problem?-Clearly, it is
statistically efficient for treatment groups
to be as similar as possible with respect to
prognostic factors. However, in trials of
reasonable size the loss of efficiency is
unlikely to be very substantial if im-
balance were to arise from unstratified
randomization. Futhermore, ifthe statisti-
cal analysis of treatment differences
adjusts for such patient factors (e.g. by
retrospective stratification or by an analy-
sis ofcovariance methods) loss ofefficiency
usually becomes negligible (see Peto et al.,
1976, section 12). Thus, on scientific
grounds alone, imbalance is not of serious
consequence. Rather the main problem is a
certain loss of credibility associated with
non-comparable treatment groups. Clinic-
ians may become more sceptical of trial
conclusions if the use of statistical adjust-
ments makes the results less immediate
and comprehensible.
Is stratification worthwhile?-It should
be noted that many trials would end up
reasonably well balanced even if no
stratification were used. Thus, stratifica-
tion is like an insurance policy to
guarantee such balance. The greatest
advantage over non-stratified randomiza-
tion is the safeguard against the unlikely
event of a sizeable treatment difference in
one or more patient factors. The larger a
trial becomes the less important is stratifi-
cation since the chances of imbalance are
progressively reduced. However, even in
the largest of trials, ifinterim analysis are
required one should contemplate strati-
fication at least in the early stages. In any
size oftrial, it may be advisable to stratify
or otherwise balance for institution.
One's decision on how much stratific-
ation must be a compromise between the
ideal of achieving perfect balance and the
feasibility of day-to-day running of a
randomization centre. If there is any
serious doubt that stratification may be
unreliably carried out, it may be better to
opt for a simple unstratified scheme.
Reliabilityandsimplicity.-Oneessential
in any randomization procedure is that it
should work in practice easily for every
patient entered. Hence, one should avoid
undue complexity in the cause of exact
scientific design. One should aim for a
system which is effective in ensuring that
protocol is followed, with only those
methods to achieve good balance that can
be implemented by the resources available
at the randomization centre.
We are very grateful to the members of the cancer
centres participating in our survey for their help so
willingly offered. We express our thanks to Laurence
Freedman of the M.R.C. Cancer Trials Office for the
minimization example. WVe are also indebted to the
other members of the U.T.C.C. Project on Controlled
Therapeutic Trials for their helpful comments on
this work.
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